This page shows the latest myelofibrosis news and features for those working in and with pharma, biotech and healthcare.
It is approved across a number of indications, including for the treatment of polycythemia vera (PV), intermediate- or high-risk myelofibrosis (MF) and post-essential thrombocythemia MF.
Ruxolitinib is already on the market in oral form under the Jakafi/Jakavi brand names as a treatment for myelofibrosis, a type of bone marrow cancer.
It was cleared for use in myelofibrosis – a rare bone marrow disorder. ... Some analysts have predicted that Inrebic could also become a $1bn product in myelofibrosis, despite a black-box warning on its label for a serious and life-threatening brain
associated with scarring of the lungs, as well as early-stage results in myelofibrosis. ... That mechanism suggests PRM-151 could have potential in a range of diseases characterised by fibrosis, including myelofibrosis – a haematological cancer that
That includes continuing clinical development of anti-KIR3DL2 antibody IPH4102 for the treatment of patients with Sézary syndrome – a form of cutaneous T cell lymphoma (CTCL) – as well as myelofibrosis and
Currently in the middle of merger. After a turbulent development, Celgene has finally claimed FDA approval for Inrebic, its new drug for rare bone marrow disorder myelofibrosis. ... That deal is worth up to $7bn but is weighted to fedratinib’s
More from news
Approximately 9 fully matching, plus 41 partially matching documents found.
Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis
The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company - remaining 90%. 9
Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐2 protein for idiopathic pulmonary fibrosis and myelofibrosis.
Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal
It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100,
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
He just never makes any time for me.”. Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.
Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...